Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Taiwain Researchers Report New Marker For Liver Cancer Risk

This article was originally published in PharmAsia News

Executive Summary

Taiwan scientists report discovery of a new biomarker for liver cancer, one related to the hepatitis B virus. The researchers said identifying the indicator could aid in new diagnostic procedures. The research, to be published in the next issue of the Journal of the National Cancer Institute, suggests a patient with genotype C has as much as double the risk of developing cancer as one with genotype B of the hepatitis B virus. Further, if the virus has mutated, the risk changes up or down according to where the mutation occurs. (Click here for more

Latest Headlines
See All
UsernamePublicRestriction

Register

SC069282

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel